Pharos is a powerful, single-wavelength, xenon-chlorine, 308 nm ultraviolet-B excimer laser used by physicians as a tool to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis, and leukoderma. Pharos does not use heat and does not ablate lesions, and treatments are generally painless. Pharos’ proprietary hand piece features an integrated adjustable spot size and aiming beam that accurately targets only the diseased tissue while sparing the healthy skin from exposure. The laser beam is easily contoured to accommodate the shape of the lesion for fast and precisely targeted treatments with constant fluence. No templates or attachments are required. Its flat-top, no hot-spot beam profile delivers uniform dosing for optimal results. Pharos is small enough for most treatment rooms, intuitive to use, and uses a standard 110-volt outlet.
The FDA has granted 510(k) clearance to market Pharos in the U.S. for psoriasis, vitiligo, atopic dermatitis, and leukoderma. We have also received clearance to market Pharos from the European Medicines Agency, or EMA, China Food and Drug Administration, or CFDA, and South Korea Ministry of Drug Safety, or KFDA.
Pharos offers significant benefits to patients. The targeted nature of Pharos treatment allows the operator to spare healthy tissue from exposure to the ultraviolet light making the treatment faster and safer than some other forms of phototherapy, or light therapy. Treatment with Pharos differs from topical treatments, such as steroids and vitamin D derivatives, which may require frequent ongoing application. Treatment with Pharos also differs from pharmaceuticals treatments, which may be associated with systemic side effects.
- Wavelength. Pharos is a 308-nanometer laser, making it ideally suited for use as a tool in the treatment of immunologically modulated skin disorders. Studies have shown that the action spectrum for these diseases is centered at about 308 nanometers.
- Energy. Pharos is a pulsed laser capable of producing very high peak powers. The energy from excimer lasers has been shown, in both in vivo and in vitro studies, to have almost four times the T-cell apoptosis generation than non-laser sources.
- Collimation. Although the skin tends to scatter the light, collimation, or keeping the light rays parallel, helps prevent reflection and improves the dose delivery.
- Targeting. Pharos has an integrated adjustable spot size offering continuous beam adjustment from a large square to a small circle. Applying the laser energy only to the diseased tissue spares the healthy tissue from exposure, and also allows the operator to increase the dose to only the affected areas.
- Footprint. Pharos has a small footprint and is among the lightest excimer lasers currently marketed, allowing physicians to conserve space and easily move the system.
Pharos is reimbursed using established Current Procedural Terminology, or CPT, codes 96920, 96921, and 96922 for excimer laser treatment of inflammatory skin disease.
|Spot Size|| Continuously Adjustable from 3.24 cm2|
to 2 mm round with constant fluence
|Beam Profile||Flat-Top, Non-Gaussian|
|Firing Device||Fingerfire Handpiece or Footpedal|
|Delivery||1.5 m or 2 m Liquid Filled Fiber Optic|
|Weight||106 lbs (48 kgs)|
|Size||14” W x 27” L x 32″ T (36 cm W x 68 cm L x 82 cm T)|
|Electrical Inputs||115 VAC, 6 A, 47 Hz to 63 Hz / 230 VAC, 3 A, 47 Hz to 63 Hz|